OBJECTIVES: To define most potential drugs (MPD) for budget optimization and complex assessment of added value and cost-effectiveness in breast cancer patients in Moscow.

METHODS: We conducted retrospective cabinet analysis of drug utilization and drug cost. Main data source was regular database of reimbursed drug prescription of Moscow department of healthcare. The database included depersonalized data about drug prescription. We computed number of patients received each drug, number of prescriptions, mean cost of drugs per patient, total cost of drugs for all patients within 2017 year. Then we calculated percent of drug costs in all drug costs, which reflects of budget impact, and percent of prescription in all prescriptions, which reflects of real needs. Also, we developed and calculated "prioritization coefficient" (PC; share of costs / share of prescriptions). This complex coefficient reflects relative cost per patient, cost per all patients, and number of prescriptions, and helps to indicate MPD.

RESULTS: CONCLUSIONS: We defined the list of MPD to be focused on with complex assessment in breast cancer patients in Moscow.